Filing summary: TapImmune Inc. Form 10-K
Entity and period: The supplied filing is for TapImmune Inc., not Marker Therapeutics, Inc. It is an annual report for the fiscal year ended December 31, 2012, filed May 15, 2013; it is not a standalone 2012 fourth-quarter report.
Business context
TapImmune described itself as a development-stage immunotherapy company with no products on the market and no revenue since inception. Its programs focused on TAP-based vaccine technology, including a HER2/neu breast cancer vaccine being evaluated in a Mayo Clinic Phase I trial, and infectious-disease/biodefense applications. The company planned to advance oncology programs and pursue collaborations and grant funding for infectious-disease work.
Financial results and liquidity
| Metric | FY 2012 / year-end | FY 2011 / comparison |
|---|---|---|
| Revenue | None reported | None reported |
| Net loss | $5.858 million in the audited statements; $0.09 per share | $2.029 million; $0.04 per share |
| Operating expenses | $6.223 million in the audited statements | $3.316 million |
| Cash from operations | $(1.565) million | $(1.310) million |
| Cash from financing | $1.366 million | $1.537 million |
| Cash at year-end | $50,679 | $250,234 |
| Working capital | $(5.468) million, as reported in MD&A | $(3.493) million |
| Total current liabilities | $5.771 million | $3.801 million |
| Convertible notes payable | $1.376 million carrying amount | $999,000 |
Margins are not meaningful because the company reported no revenue. The balance sheet also included $1.475 million of derivative liabilities, $2.059 million of accounts payable and accrued liabilities, and $416,000 of research-agreement obligations. The filing separately gives working capital excluding derivative liabilities as a deficit of $4.191 million.
Changes and unusual items
- Net loss increased substantially year over year. Research and development expense rose to $1.057 million from $204,000, and stock-based consulting expense increased to $2.316 million from $872,000. General and administrative expense also rose to $1.012 million from $306,000.
- Stock-based compensation and share issuance were significant: 76.4 million common shares were outstanding at year-end, versus 52.1 million a year earlier. The company reported 16.9 million warrants outstanding at year-end and separately disclosed 7.943 million options outstanding as of the report date.
- The audited statements report a $536,527 gain from changes in fair value of derivative liabilities. This non-cash accounting item partially offset the loss.
- MD&A figures do not fully reconcile to the audited statements: it cites net loss of $5.660 million, operating expenses of $6.025 million, and professional fees of $350,000, while the statements show $5.858 million, $6.223 million, and $489,537, respectively. The filing text does not explain these differences.
Outlook, risks, and contingencies
- Management estimated spending of approximately $5 million over the following 12 months, but stated that cash and working capital were insufficient to fund operations. It had no financing commitments and said failure to secure acceptable funding could force it to scale back or abandon its plan.
- The auditor included a going-concern emphasis; the filing states that substantial doubt exists about the company’s ability to continue as a going concern. Accumulated losses since inception were $49.580 million.
- The company reported defaults on February 2011 secured notes after missed 2013 amortization payments; default interest was to rise to 20%. It also reported a default on an October 2012 note due to late filing, which management expected to cure upon filing.
- Crucell research-license obligations were delinquent; the licensor could cancel the agreement. Research and consulting commitments totaled approximately $1.208 million for 2013 and 2014 combined. The Mayo agreement contemplated costs up to $841,000, including an initial $250,000 payment when the trial was to commence.
- Two consultants threatened legal action over disputed share issuances. The filing also describes 14 million shares issued to consultants and, elsewhere, 11.2 million shares whose validity the company contested; the relationship between these disclosures is not clear from the filing text.
- Management reported ineffective disclosure controls and material weaknesses in internal control over financial reporting, including limited oversight, inadequate segregation of duties, and insufficient written accounting and reporting procedures.
- The Phase I HER2/neu trial had begun patient dosing, and interim safety review of the first five patients was reported as successful. Clinical efficacy, regulatory approval, and commercialization remained uncertain.
Important facts for investors to verify
- Confirm the issuer identity: this filing names TapImmune Inc., whereas the request metadata names Marker Therapeutics, Inc.
- Reconcile the MD&A loss and expense figures with the audited financial statements.
- Verify current financing, debt balances, defaults, creditor discussions, and the company’s ability to meet near-term obligations.
- Check the status and terms of disputed consultant share issuances, subsequent share counts, convertible securities, warrants, and potential dilution.
- Review subsequent clinical-trial progress, Mayo and Crucell agreement status, and remediation of reported control weaknesses.